Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Keywords

AtezolizumabBevacizumabMedicineSorafenibInternal medicineHazard ratioHepatocellular carcinomaOncologyPopulationClinical endpointProgression-free survivalGastroenterologySurgeryRandomized controlled trialCancerConfidence intervalChemotherapyNivolumabImmunotherapy

Affiliated Institutions

Related Publications

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , George Lau , Masatoshi Kudo +28 more

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion reg...

2022 NEJM Evidence 1193 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet , Florian Castet , Mathias Heikenwälder +6 more

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patie...

2021 Nature Reviews Clinical Oncology 1590 citations

Publication Info

Year: 2021
Type: article
Volume: 76
Issue: 4
Pages: 862-873
Citations: 1397
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1397

OpenAlex

Cite This

APA Style

                            
                                
                                    Ann‐Lii Cheng, 
                                
                                    Shukui Qin, 
                                
                                    Masafumi Ikeda
                                
                                et al.
                            
                            (2021). 
                            Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. 
                            Journal of Hepatology
                            , 76
                            (4)
                            , 862-873.
                            https://doi.org/10.1016/j.jhep.2021.11.030
                        

Identifiers

DOI: 10.1016/j.jhep.2021.11.030